Systemic therapies are critical to the treatment of muscle-invasive bladder cancer (MIBC) and locally advanced/metastatic bladder cancer. Recent approvals and clinical trial results continue to enhance the treatment landscape in this space.

Systemic therapies are critical to the treatment of muscle-invasive bladder cancer (MIBC) and locally advanced/metastatic bladder cancer. Recent approvals and clinical trial results continue to enhance the treatment landscape in this space.

Recent approvals and clinical trial results continue to enhance treatment options for both BCG-resistant non-muscle invasive bladder cancer and locally advanced/metastatic bladder cancer. Clinicians should be knowledgeable in these recent updates as well as understand how to apply them to their clinical practice.

The goal of this program is to improve the knowledge, competence, and performance of learners in effort to optimize treatment for patients with bladder cancer.

This activity will help clinicians identify the best treatment options for their patients with bladder cancer.

This activity will help clinicians identify the best treatment options for their patients with bladder cancer.

Systemic therapy options for advanced bladder cancer continue to expand. The approvals of new therapies or combinations of therapies and emerging clinical trial data continue to impact the treatment landscape, and education on the topic would be valuable to help clinicians stay up to date with the latest research

These NCCN Guidelines Insights detail recent updates to the NCCN Guidelines for Bladder Cancer, including changes in the fifth edition of the WHO Classification of Tumours: Urinary and Male Genital Tumours and how the NCCN Guidelines aligned with these updates; new and emerging treatment options for bacillus Calmette-Guérin (BCG)–unresponsive NMIBC; and updates to systemic therapy recommendations for advanced or metastatic disease.